FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAffimed N.V.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
AFMDQ
Affimed N.V. Stock AnalysisComprehensive stock analysis for Affimed N.V. (AFMDQ) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAFMDQ
AFMDQ
Affimed N.V.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
AFMDQ
  1. Home
  2. Stocks
  3. Affimed N.V.

Affimed N.V.

🇺🇸AFMDQ•PNK

Affimed N.V.

🇺🇸AFMDQ•PNK

Your view on AFMDQ

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Affimed N.V.

Industry
Biotechnology
Sector
Healthcare
CEO
Shawn Leland
Headquarters
Gottlieb-Daimler-Straße 2, Mannheim, BW, DE
Industry
Biotechnology
Sector
Healthcare
CEO
Shawn Leland
Headquarters
Gottlieb-Daimler-Straße 2, Mannheim, BW, DE
Description

Affimed N.V. operates as a clinical-stage biopharmaceutical firm, dedicated to the discovery and advancement of immunotherapies targeting cancer across both the United States and Germany.

Its primary therapeutic candidates include AFM13, which has successfully concluded Phase 2 trials for CD30-positive lymphoma, Phase 1b for Hodgkin lymphoma, and Phase 2b clinical evaluation for peripheral T-cell lymphoma.

Another key candidate, AFM24, a tetravalent, bispecific innate cell engager designed to bind epidermal growth factor receptor and CD16A, is currently undergoing a Phase 2a clinical trial for patients with advanced malignancies. Additionally, AFM28, another innate cell engager (ICE), is in preclinical stages for addressing acute myeloid leukemia.

Similarly, AFM32, an ICE candidate, is progressing through preclinical development for solid tumor indications. The company also maintains a collaborative partnership with Artiva Biotherapeutics, aiming to develop the combined therapy of acimtamig and AlloNK.

Furthermore, a licensing and strategic alliance with Roivant Sciences Ltd. focuses on the development and commercialization of new ICE molecules, notably AFM32, within the field of oncology.

A strategic collaboration with Genentech is also in place for advancing specific product candidates, encompassing novel NK cell engager-based immunotherapeutic agents designed to combat a range of cancers. Formerly named Affimed Therapeutics B.V., the entity adopted its current moniker, Affimed N.V., in October 2014.

Established in 2000, its corporate headquarters are situated in Mannheim, Germany.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Affimed N.V.. Starting points for Affimed N.V.: EPS -$7.09, beta 0.31 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Affimed N.V.. Affimed N.V. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Affimed N.V.. Trailing twelve-month EPS for Affimed N.V. stands at -$7.09. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
Analysts' targetEUR 7.50average of analysts' targets
Current price—

Buy

Targets, low to high

$7.50

Low $5.00

Middle $7.50

High $10.00

Analyst ratings

14 ratings
  • Strong Buy0
  • Buy9
  • Hold5
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2024Next quarterMar 2025This yearYear to Dec 2024Next yearYear to Dec 2025
Average estimate−EUR 0.80−EUR 0.48−EUR 4.06−EUR 1.74
Lowest estimate−EUR 0.80−EUR 0.48−EUR 4.06−EUR 1.74
Highest estimate−EUR 0.80−EUR 0.48−EUR 4.06−EUR 1.74
Number of analysts1111
A year ago−EUR 1.70−EUR 1.35−EUR 7.09—
Growth vs a year ago+52.8%+64.2%+42.8%—

Revenue estimates

TotalThis quarterDec 2024Next quarterMar 2025This yearYear to Dec 2024Next yearYear to Dec 2025
Average estimateEUR 1.20MEUR 1.30MEUR 1.79MEUR 8.17M
Lowest estimateEUR 1.20MEUR 1.30MEUR 1.79MEUR 8.17M
Highest estimateEUR 1.20MEUR 1.30MEUR 1.79MEUR 8.17M
Number of analysts1111
A year agoEUR 1.96MEUR 413000.00EUR 8.28M—
Growth vs a year ago−38.8%+214.3%−78.4%—
Recent rating and target changes (15)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Affimed N.V.. Affimed N.V. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold AFMDQ12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
NTRBWNutriband Inc.HealthcareNASDAQ$76.8M
NTRRNeutra Corp.HealthcareOTC$291,790
NURPFNeuren Pharmaceuticals LimitedHealthcareOTC$1.1B
NUVBNuvation Bio Inc.HealthcareNYSE$1.3B
NUZ.AXNeurizon Therapeutics LimitedHealthcareASX—
NVAXNovavax, Inc.HealthcareNASDAQ$1.2B
NVCTNuvectis Pharma, Inc.HealthcareNASDAQ$666.8M
NWBONorthwest Biotherapeutics, Inc.HealthcareOTC$359.4M
NWPHFNewron Pharmaceuticals S.p.A.HealthcareOTC$239.5M
NXTCNextCure, Inc.HealthcareNASDAQ$29.5M
NYMXFNymox Pharmaceutical CorporationHealthcareOTC$4.8M
NYR.AXNyrada Inc.HealthcareASX—
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Affimed N.V.

AFMDQ AnalysisWeak
Past
2
Growth
1
Health
4
Profit
1
Value
1